Segment Information (Tables)

12 Months Ended

Dec. 31, 2011

Segment Information [Abstract]

Schedule Of Financial Data For Two Business Segments

	For the Years Ended December 31,
	2011			2010			2009
Revenues:
Par Pharmaceutical	$	834,592		$	916,930		$	1,104,295
Strativa		91,546			91,944			88,864
Total revenues	$	926,138		$	1,008,874		$	1,193,159
Gross margin:
Par Pharmaceutical	$	320,313		$	305,716		$	267,830
Strativa		66,431			67,815			66,123
Total gross margin	$	386,744		$	373,531		$	333,953
Operating (loss) income:
Par Pharmaceutical	$	(10,973	)	$	169,882		$	163,186
Strativa		(39,620	)		(36,961	)		(31,716	)
Total operating (loss) income	$	(50,593	)	$	132,921		$	131,470
Gain on bargain purchase		-			-		$	3,021
Loss on extinguishment of senior         subordinated convertible notes		-			-		($	2,598	)
Gain (loss) on marketable securities and         other investments, net		237			3,459			(55	)
Interest income		736			1,257			2,658
Interest expense		(2,676	)		(2,905	)		(8,013	)
(Benefit) provision for income taxes		(5,996	)		41,980			48,883
(Loss) income from continuing operations	$	(46,300	)	$	92,752		$	77,600

Schedule Of Total Revenues Of Top Selling Products

Product	For the Years Ended December 31,
	2011		2010		2009
Par Pharmaceutical
Metoprolol succinate ER (Toprol-XL®)	$	250,995	$	473,206	$	742,697
Budesonide (Entocort® EC)		70,016		-		-
Propafenone (Rythmol SR®)		69,835		-		-
Sumatriptan succinate injection (Imitrex®)		64,068		72,984		72,319
Chlorpheniramine/Hydrocodone (Tussionex®)		39,481		17,479		-
Amlodipine and Benazepril HCl (Lotrel®)		37,310		-		-
Dronabinol (Marinol®)		29,880		27,232		24,997
Tramadol ER (Ultracet ER®)		24,980		22,640		5,520
Meclizine Hydrochloride (Antivert®)		17,184		31,216		38,851
Cholestyramine Powder (Questran®)		16,144		16,007		13,092
Nateglinide (Starlix®)		15,157		15,287		7,001
Omeprazole (Zegerid®)		14,926		18,476		-
Cabergoline (Dostinex®)		12,186		12,487		12,895
Megestrol oral suspension (Megace®)		11,959		12,556		11,830
Methimazole (Tapazole®)		8,756		10,649		10,062
Clonidine TDS (Catapres TTS®)		4,094		61,272		33,747
Propranolol HCl ER (Inderal LA®)		154		5,870		12,473
Other (1)		117,490		103,326		112,079
Other product related revenues (2)		29,977		16,243		6,732
Total Par Pharmaceutical Revenues	$	834,592	$	916,930	$	1,104,295
Strativa
Megace® ES	$	58,172	$	60,879	$	68,703
Nascobal® Nasal Spray (3)		21,399		17,715		10,161
Oravig®		2,434		1,137		-
Zuplenz®		875		213		-
Other product related revenues (2)		8,666		12,000		10,000
Total Strativa Revenues	$	91,546	$	91,944	$	88,864

(1)	The further detailing of revenues of the other approximately 35 generic drugs is impracticable due to the low volume of revenues associated with each of these generic products. No single product in the other category is in excess of 3% of total generic revenues for any year in the three-year period ended December 31, 2011.
(2)	Other product related revenues represents licensing and royalty related revenues from profit sharing agreements related to products such as doxycycline monohydrate, the generic version of Adoxa®, diazepam rectal gel, the generic version of Diastat®, and fenofibrate, the generic version of Tricor®. Other product related revenues included in the Strativa segment relate to a co-promotion arrangement with Solvay for Androgel®, and the $2 million termination payment associated with the discontinuation of the co-promotion arrangement with Solvay in December 2010. On January 30, 2009, the FTC filed a lawsuit against us in the U.S. District Court for the District of Central California alleging violations of antitrust laws stemming from our court-approved settlement in the patent litigation with Unimed and Besins (see "Legal Proceedings" in Note 17, "Commitments, Contingencies and Other Matters").
(3)	Refer to Note 21, "2009 Acquisitions."